Piper Sandler analyst Christopher J. Raymond reiterated an Overweight rating and $76.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at JefferiesMarch 5, 2025 5:21 AM Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300March 3, 2025 7:31 AM Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300March 3, 2025 7:31 AM Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 7:30 AM